Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

CVS Health blew past first-quarter earnings estimates early Thursday, while raising its full-year outlook by a smaller amount. The pharmacy and health benefits giant also announced an agreement to ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as Novo Nordisk expands patient access ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Cigna (NYSE:CI) on Friday announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the ...

CVS Health (CVS) is maintaining Thursday gains ahead of the closing bell after outpacing top and bottom line expectations, ...

The winner of the first major head-to-head study of weight loss jabs has been revealed.

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

And that's hard to do," Ricks said of the CVS deal. He also noted that the company's direct ... Eli Lilly has been on ...